Lihat Juga

• Supplementary Appendix - Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study
  oleh: Paller, Amy
  Terbitan: (2019)
• Supplementary file - Efficacy and safety of methotrexate add-on therapy versus placebo for patients with chronic spontaneous urticaria resistant to H1-antihistamines: a randomized, controlled trial
  oleh: Leducq, Sophie
  Terbitan: (2019)
• DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)
  oleh: Shears, Gill
  Terbitan: (2019)
• Supplemental material for "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)"
  oleh: Lebwohl, Mark
  Terbitan: (2019)
• Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate to severe ARDS in a randomized, placebo-controlled, double-blind trial: preliminary evaluation of safety and feasibility in light of the COVID- 19 pandemic
  oleh: Schmid, Benedikt, et al.
  Terbitan: (2022)